U. Vanhoefer

4.2k total citations
84 papers, 3.1k citations indexed

About

U. Vanhoefer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, U. Vanhoefer has authored 84 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 30 papers in Molecular Biology. Recurrent topics in U. Vanhoefer's work include Colorectal Cancer Treatments and Studies (42 papers), Gastric Cancer Management and Outcomes (37 papers) and Cancer Treatment and Pharmacology (30 papers). U. Vanhoefer is often cited by papers focused on Colorectal Cancer Treatments and Studies (42 papers), Gastric Cancer Management and Outcomes (37 papers) and Cancer Treatment and Pharmacology (30 papers). U. Vanhoefer collaborates with scholars based in Germany, United States and Belgium. U. Vanhoefer's co-authors include A. Harstrick, S. Seeber, Youcef M. Rustum, H. Wilke, W. Achterrath, Shousong Cao, N. Schleucher, Eric Van Cutsem, J. Wils and Bernard Nordlinger and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

U. Vanhoefer

80 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
U. Vanhoefer Germany 29 2.1k 1.2k 967 577 280 84 3.1k
Tetsuhiko Shirasaka Japan 24 2.4k 1.2× 1.9k 1.6× 749 0.8× 845 1.5× 250 0.9× 102 3.5k
Axel Grothey United States 29 2.6k 1.3× 1.4k 1.2× 896 0.9× 685 1.2× 370 1.3× 93 3.8k
Noriaki Sawada Japan 11 2.5k 1.2× 735 0.6× 465 0.5× 517 0.9× 256 0.9× 20 3.0k
Kun He United States 27 2.0k 1.0× 1.3k 1.0× 835 0.9× 230 0.4× 209 0.7× 53 3.2k
André Planting Netherlands 31 1.6k 0.8× 720 0.6× 923 1.0× 362 0.6× 105 0.4× 71 2.6k
Richard C. Chao United States 28 2.9k 1.4× 1.4k 1.1× 1.3k 1.3× 176 0.3× 179 0.6× 90 4.1k
Muhammad Wasif Saif United States 25 1.7k 0.8× 639 0.5× 562 0.6× 475 0.8× 180 0.6× 129 2.7k
Elizabeth Poplin United States 24 2.2k 1.1× 1.2k 1.0× 681 0.7× 721 1.2× 281 1.0× 80 3.2k
J. L. Misset France 27 2.1k 1.0× 1.0k 0.9× 433 0.4× 452 0.8× 419 1.5× 63 3.0k
Heike Richly Germany 20 1.2k 0.6× 736 0.6× 1.1k 1.1× 181 0.3× 360 1.3× 56 2.4k

Countries citing papers authored by U. Vanhoefer

Since Specialization
Citations

This map shows the geographic impact of U. Vanhoefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Vanhoefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Vanhoefer more than expected).

Fields of papers citing papers by U. Vanhoefer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Vanhoefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Vanhoefer. The network helps show where U. Vanhoefer may publish in the future.

Co-authorship network of co-authors of U. Vanhoefer

This figure shows the co-authorship network connecting the top 25 collaborators of U. Vanhoefer. A scholar is included among the top collaborators of U. Vanhoefer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Vanhoefer. U. Vanhoefer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Porschen, Rainer, Wolfgang Fischbach, Ines Gockel, et al.. (2023). S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Zeitschrift für Gastroenterologie. 61(6). 701–745. 1 indexed citations
2.
Porschen, Rainer, Wolfgang Fischbach, Ines Gockel, et al.. (2023). S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Zeitschrift für Gastroenterologie. 61(6). e209–e307.
3.
Köhne, Claus‐Henning, U. Vanhoefer, & G. Hartung. (2009). Clinical predictive factors. European Journal of Cancer. 45. 43–49. 2 indexed citations
4.
Sauer, Rolf, Andrea Tannapfel, Claus Rödel, et al.. (2007). Die Therapie des Rektumkarzinoms. Oncology Research and Treatment. 30(2). 18–22. 2 indexed citations
5.
Pieńkowski, Tadeusz, et al.. (2006). Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemotherapy and Pharmacology. 59(6). 703–709. 3 indexed citations
6.
Braun, Ada, et al.. (2005). The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anti-Cancer Drugs. 16(10). 1099–1108. 25 indexed citations
7.
Trarbach, Tanja, Thomas Beyer, N. Schleucher, et al.. (2004). A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. Journal of Clinical Oncology. 22(14_suppl). 3018–3018. 4 indexed citations
8.
Trarbach, Tanja, Thomas Beyer, N. Schleucher, et al.. (2004). A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. Journal of Clinical Oncology. 22(14_suppl). 3018–3018. 11 indexed citations
9.
Bojko, Peter, Anja Welt, Regina Schleucher, et al.. (2004). High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplantation. 34(7). 637–643. 10 indexed citations
10.
Thomas, Aurélie, Bruno Morgan, Joachim Drevs, et al.. (2003). Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Seminars in Oncology. 30(3). 32–38. 86 indexed citations
11.
Tewes, Mitra, N. Schleucher, W. Achterrath, et al.. (2003). Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study†. Annals of Oncology. 14(9). 1442–1448. 46 indexed citations
12.
Beckers, Thomas, Thomas Reissmann, Mathias Schmidt, et al.. (2002). 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.. PubMed. 62(11). 3113–9. 42 indexed citations
13.
Bacher, Gerald, B Nickel, Peter Emig, et al.. (2001). D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.. PubMed. 61(1). 392–9. 131 indexed citations
14.
Guo, Bin, Wieland Voigt, U. Vanhoefer, et al.. (1998). Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1401(3). 265–276. 6 indexed citations
15.
Vanhoefer, U., Wieland Voigt, Ralf A. Hilger, et al.. (1997). Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.. PubMed. 9(9). 485–94. 5 indexed citations
16.
Vanhoefer, U., Shousong Cao, A. Harstrick, S. Seeber, & Youcef M. Rustum. (1997). Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Annals of Oncology. 8(12). 1221–1228. 63 indexed citations
17.
18.
19.
Stahl, M., U. Vanhoefer, U. Fink, et al.. (1996). Phase II Study of Weekly High-Dose 5-Fluorouracil and Folinic Acid plus Biweekly Alternating Cisplatin and Epirubicin (FUFACE) in Patients with Advanced Gastric Carcinoma. Oncology Research and Treatment. 19(5). 416–418. 6 indexed citations
20.
Wilke, Hans‐Joachim, U. Klaassen, W. Achterrath, et al.. (1996). Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Annals of Oncology. 7(1). 55–58. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tetsuhiko Shirasaka Breakdown of academic impact, for papers by Axel Grothey Breakdown of academic impact, for papers by Noriaki Sawada Breakdown of academic impact, for papers by Kun He Breakdown of academic impact, for papers by André Planting Breakdown of academic impact, for papers by Richard C. Chao Breakdown of academic impact, for papers by Muhammad Wasif Saif Breakdown of academic impact, for papers by Elizabeth Poplin Breakdown of academic impact, for papers by J. L. Misset Breakdown of academic impact, for papers by Heike Richly
Rankless by CCL
2026